O.5.2-7 Listening to the patients’ voice: a conceptual framework of the walking experience

Abstract

Abstract Purpose Walking is crucial for an active and healthy ageing, but it changes with age and in the presence of diverse health conditions, such as non-communicable diseases and injuries. So far, conceptual frameworks of walking have not included the impact of these conditions and individuals’ lived experiences on their walking. Thus, we aimed to identify and synthesize evidence describing the walking experience from the perspective of individuals living with highly prevalent walking-impairing conditions of diverse aetiology (i.e., Parkinson’s disease, multiple sclerosis, chronic obstructive pulmonary disease, heart failure, hip fracture, frailty and sarcopenia). Methods We conducted a systematic review and meta-ethnography of qualitative evidence, following appropriate guidance. Results Out of 2,552 unique records, 117 were deemed eligible for the meta-ethnographic synthesis. We identified seven common themes that explain the experience of walking: (1) becoming aware of the walking experience, (2) the walking experience as a link between individuals’ activities and sense of self, (3) the physical walking experience, (4) the mental and emotional walking experience, (5) the social walking experience, (6) the context of the walking experience, and (7) behavioral and attitudinal adaptations resulting from the walking experience. Conclusion We proposed a framework that describes the interplay between these themes, providing a conceptualization of walking that is grounded in the experiences of individuals recovering from a hip fracture or living with other walking-impairing health conditions, and that may be used to set priorities and improve patient centricity in clinical practice, research and public health initiatives. Support/Funding Source This work was supported by the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).